Amgen Wins Appeal Over Cipla’s Bid to Sell Generic Cancer Drug

A U.S. appeals court, without issuing a formal opinion, affirmed a trial court ruling that will prevent Cipla from selling a generic version of the Kyprolis injectable cancer treatment made by Amgen’s Onyx unit.

• Cipla had argued that the court in Delaware was wrong last year when he upheld two patents covering the compound used to make the drug
• The patents expire in 2025 and 2026: FDA Orange Book
• NOTE: Kyprolis had $719m in U.S. sales last year for Amgen, according to data compiled by Bloomberg
• Three-judge panel of the U.S. Court of Appeals for the Federal Circuit heard arguments ...